Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients

Inclusion Criteria: * 18-74 years of age * Within 50% of ideal body weight and greater than 40 kg * Chronic kidney disease (CKD) stage 5 receiving maintenance hemodialysis for at least 3 months * Native kidney estimated glomerular filtration rate(GFR) \< 10 mL/min * No concurrent illness or evidence of infection * Able to give informed consent Exclusion Criteria: * QTc interval \> 470 msec at echocardiogram (ECG) obtained within the last 6 months * Concomitant QT-prolonging drugs, major P-gp inhibitors, and CYP3A4 inducers and inhibitors including: cyclosporine, rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, St. John's Wort, ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, saquinavir, quinidine, dofetilide, sotalol, amiodarone, erythromycin, thioridazine, ziprasidone, haloperidol, trimethoprim/sulfamethoxazole, ciprofloxacin, norfloxacin, levofloxacin, moxifloxacin * Pre-study hemoglobin \< 9.5 g/dL * Plasma albumin \< 2.5 g/dL * Liver disease - exclude subjects with a Child Pugh score of C or higher * Positive pregnancy test * Breastfeeding * Allergy to ranolazine * Participating in another investigational study * Hepatitis B infection due to dialysis isolation requirements * Unstable blood pressure control * Need for routine large fluid removal during dialysis (\> 4L)